Exact Sciences Corporation (NASDAQ:EXAS) Director Thomas D. Carey purchased 2,500 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were purchased at an average price of $37.71 per share, with a total value of $94,275.00. Following the completion of the acquisition, the director now directly owns 60,858 shares of the company’s stock, valued at $2,294,955.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Exact Sciences Corporation (NASDAQ EXAS) traded up 1.09% on Friday, hitting $37.87. 1,039,106 shares of the stock were exchanged. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $42.18. The firm’s market capitalization is $4.51 billion. The company has a 50-day moving average price of $37.99 and a 200-day moving average price of $29.42.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.10. The firm had revenue of $57.65 million during the quarter, compared to the consensus estimate of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. Equities research analysts expect that Exact Sciences Corporation will post ($1.18) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/18/exact-sciences-corporation-exas-director-thomas-d-carey-acquires-2500-shares.html.

A number of equities research analysts have issued reports on the stock. Jefferies Group LLC restated a “buy” rating and set a $25.00 price target on shares of Exact Sciences Corporation in a report on Wednesday, April 26th. Cowen and Company upped their price target on shares of Exact Sciences Corporation from $40.00 to $45.00 and gave the company an “outperform” rating in a report on Monday, May 15th. Leerink Swann set a $38.00 price target on shares of Exact Sciences Corporation and gave the company a “buy” rating in a report on Friday, April 28th. Vetr cut shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $36.37 price target for the company. in a report on Thursday, July 6th. Finally, Roth Capital restated a “buy” rating and set a $40.00 price target (up from $33.00) on shares of Exact Sciences Corporation in a report on Thursday, June 1st. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Exact Sciences Corporation currently has a consensus rating of “Buy” and a consensus target price of $40.51.

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Exact Sciences Corporation by 45,816.0% in the first quarter. BlackRock Inc. now owns 6,804,297 shares of the medical research company’s stock worth $160,718,000 after buying an additional 6,789,478 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Exact Sciences Corporation by 98.1% in the first quarter. JPMorgan Chase & Co. now owns 4,985,657 shares of the medical research company’s stock worth $117,761,000 after buying an additional 2,468,376 shares in the last quarter. Fred Alger Management Inc. acquired a new stake in Exact Sciences Corporation during the second quarter worth about $84,177,000. Point72 Asset Management L.P. increased its stake in Exact Sciences Corporation by 1,534.3% in the first quarter. Point72 Asset Management L.P. now owns 2,500,476 shares of the medical research company’s stock worth $59,061,000 after buying an additional 2,347,476 shares in the last quarter. Finally, OppenheimerFunds Inc. increased its stake in Exact Sciences Corporation by 66.8% in the first quarter. OppenheimerFunds Inc. now owns 2,502,398 shares of the medical research company’s stock worth $59,107,000 after buying an additional 1,002,398 shares in the last quarter. 85.44% of the stock is owned by hedge funds and other institutional investors.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.